Joleen Hubbard, MD, Mayo Clinic

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.

John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.

The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.

Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.

Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.

Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.